AstraZeneca digs into new Cambridge home with MRC drug deal

By Ben Hirschler CAMBRIDGE, England (Reuters) – AstraZeneca, which will complete its move to Cambridge by 2016, is already putting down roots in the ecosystem of the university city as it seeks to revitalize its drug research. Britain’s second-biggest pharmaceuticals group said on Monday it had struck an unique deal with the state-funded Medical Research Council (MRC) under which academic scientists will work alongside its staff at its new Cambridge site. Transplanting AstraZeneca to the university city in the east of England forms the centerpiece of a $2.5 billion restructuring plan by Chief Executive Pascal Soriot, who hopes closer links with academia will spark ideas and innovation. AstraZeneca has suffered a dry period in drug discovery in recent years and badly needs to find new medicines to replace blockbusters like Nexium for heartburn and Crestor for high cholesterol that will lose patent protection in a few years.